Expedition banked $165 million in a Series A round last year and cut its first deal with Fosun. Neutrophils are crucial in protecting against infections, but can drive lung inflammation when overstimulated. Stifling their activity with a drug could therefore hold promise for treating multiple respiratory conditions. “You take this pill once a day, and it can target that underlying inflammation that all the COPD patients have,” she said. Expedition recently began recruiting volunteers for what it claims is the first global Phase 2 trial of a DPP1 inhibitor in COPD.